Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ocumension Therapeutics (1477.HK)
HKD5.57
+0.70 (+14.37%)
CN HKSE Healthcare Biotechnology
Address
No. 1858 Yinzhongnan Road
Suzhou, CN
Suzhou, CN
CEO
Ye Liu
Website
ocumension.com
IPO
2020-07-10
ISIN KYG674111011
Description
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD5.57
+0.70 (+14.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
872.5K
Beta
0.40
Float Shares
297.03M
Free Float %
36.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.65% | -0.80% | -16.22% | -17.77% | -24.39% | -16.22% | -19.06% | -14.13% | -78.21% | -83.24% | -83.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5.57
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.57
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+92.8% ★ Q4'25: +257.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+48.7% ★ Q4'25: +87.2% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-39.5% Q4'25: -50.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-19.9% Q4'25: -5.0% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-4.6% ★ Q4'25: -2.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+15.0% Q4'25: +21.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-6.26× Q4'25: 1.18× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.10M
est: 16.60M (-21.1%)
|
56.15M
est: 65.65M (-14.5%)
|
158.96M
est: 170.94M (-7.0%)
|
246.37M
est: 288.64M (-14.6%)
|
417.31M
est: 416.70M (+0.1%)
|
804.35M
est: 803.71M (+0.1%)
|
1.15B
1.15B – 1.15B
+42.5% YoY
|
1.48B
1.30B – 1.65B
+29.0% YoY
|
1.89B
1.82B – 1.97B
+28.1% YoY
|
| EBITDA |
-2.26B
est: -14.77M (-15,197.2%)
|
-249.81M
est: -58.43M (-327.5%)
|
-359.98M
est: -152.16M (-136.6%)
|
-320.62M
est: -201.34M (-59.2%)
|
-188.03M
est: -290.67M (+35.3%)
|
-29.95M
est: -560.64M (+94.7%)
|
-799.11M
-799.46M – -798.75M
-42.5% YoY
|
-1.03B
-1.15B – -909.36M
-29.0% YoY
|
-1.32B
-1.37B – -1.27B
-28.1% YoY
|
| EBIT |
-2.26B
est: -15.39M (-14,617.9%)
|
-259.43M
est: -60.86M (-326.3%)
|
-400.44M
est: -158.47M (-152.7%)
|
-378.16M
est: -221.35M (-70.8%)
|
-265.09M
est: -319.56M (+17.0%)
|
-160.20M
est: -616.36M (+74.0%)
|
-878.52M
-878.91M – -878.13M
-42.5% YoY
|
-1.13B
-1.27B – -999.73M
-29.0% YoY
|
-1.45B
-1.51B – -1.40B
-28.1% YoY
|
| Net Income |
-2.26B
est: -5.02B (+55.1%)
|
-259.99M
est: -375.46M (+30.8%)
|
-402.64M
est: -300.86M (-33.8%)
|
-379.79M
est: -362.26M (-4.8%)
|
-268.27M
est: -261.00M (-2.8%)
|
-158.82M
est: -181.90M (+12.7%)
|
32.82M
29.99M – 35.66M
+118.0% YoY
|
118.99M
108.71M – 129.27M
+262.5% YoY
|
352.87M
322.39M – 383.34M
+196.6% YoY
|
| SGA |
324.67M
est: 111.03M (+192.4%)
|
253.81M
est: 439.11M (-42.2%)
|
373.79M
est: 1.14B (-67.3%)
|
279.01M
est: 531.57M (-47.5%)
|
270.99M
est: 767.42M (-64.7%)
|
446.05M
est: 1.48B (-69.9%)
|
2.11B
2.11B – 2.11B
+42.5% YoY
|
2.72B
2.40B – 3.04B
+29.0% YoY
|
3.49B
3.35B – 3.62B
+28.1% YoY
|
| EPS |
-7.47
est: -7.30 (-2.3%)
|
-0.43
est: -0.55 (+21.2%)
|
-0.64
est: -0.44 (-46.3%)
|
-0.59
est: -0.46 (-28.9%)
|
-0.39
est: -0.33 (-18.2%)
|
-0.20
est: -0.23 (+13.0%)
|
0.04
0.04 – 0.05
+118.0% YoY
|
0.15
0.14 – 0.16
+262.5% YoY
|
0.45
0.41 – 0.48
+196.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
647.32M
OE per share TTM
0.92
Owner's Yield
13.16%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
134.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 35 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.11% | 74.6K | 0.59% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 66.5K | 0.72% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.02% | 12.3K | 0.74% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 45.3K | 0.74% |
| 5 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 89.9K | 0.65% |
| 6 | State Street SPDR S&P China ETF GXC | 0.01% | 49.7K | 0.59% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 60.1K | 0.55% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 8.8K | 0.42% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 940.2K | 0.06% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 70.5K | 0.26% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-327.6K
Shares Outstanding
803.92M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ye Liu | Chief Executive Officer & Executive Director | 7M | male |
| Zhaopeng Hu | Chief Development Officer & Executive Director | 3M | — |
| Tim Ruan | Chief Financial Officer & Joint Company Secretary | — | male |
| Hongying Liu | Chief Manufacturing Officer and Head of Manufacture | — | female |
| Yang Shen | Chief Medical Officer | — | — |
| Tingchan Chen | Joint Company Secretary | — | female |
| Qinglei Zuo | Chief Commercial Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1477.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
